- Nano cap Hemispherx Biopharma (HEB) jumps 46% premarket on increased volume in response to its announcement that lead product candidate Ampligen (rintatolimod) has been approved for sale in Argentina for the treatment of severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). According to the company, this is the first drug to gain regulatory approval to treat ME/CFS anywhere in the world.
- It will be marketed by the company's commercial partner in Latin America, GP Pharm. Efforts to expand access to other Latin America countries, and certain countries in Europe, are underway.
-
Ampligen is an experimental therapeutic in a new class of specifically-configured RNA compounds for the treatment of diseases with immunologic defects and/or viral causation. It's been "experimental" for 25 years so investors should rely on thorough due diligence here.